Initial virologic response and HIV drug resistance among HIV-Infected individuals initiating first-line antiretroviral therapy at 2 clinics in Chennai and Mumbai, India

Clinical Infectious Diseases

Volumn 54, Issue SUPPL. 4, 2012, Pages

  Hingankar, Nitin K ^a   Thorat, Smita R ^a   Deshpande, Alaka ^b   Rajasekaran, S ^c   Chandrasekar, C ^c   Kumar, Suria ^c   Srikantiah, Padmini ^d   Chaturbhuj, Devidas N ^a   Datkar, Sharda R ^a   Deshmukh, Pravin S ^e   Kulkarni, Smita S ^a   Sane, Suvarna ^a   Reddy, D C S ^d   Garg, Renu ^d   Jordan, Michael R ^d,f   Kabra, Sandhya ^g   Tripathy, Srikanth P ^a   Paranjape, Ramesh S ^a  

^a Maharashtra Industrial Development Corporation India   (India)

^b J J Hospital   (India)

^c Government Hospital for Thoracic Medicine   (India)

^d WORLD HEALTH ORGANIZATION   (Switzerland)

^e UNIVERSITY COLLEGE OF MEDICAL SCIENCES   (India)

^f TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g Tufts University School of Medicine ^*  (India)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; STAVUDINE; ZIDOVUDINE;

ADULT; ANTIVIRAL RESISTANCE; CD4 LYMPHOCYTE COUNT; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INDIA; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; VIRUS LOAD;

ADULT; AMBULATORY CARE FACILITIES; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; CHI-SQUARE DISTRIBUTION; DRUG RESISTANCE, VIRAL; FEMALE; HIV; HIV INFECTIONS; HUMANS; INDIA; LOST TO FOLLOW-UP; MALE; MULTIVARIATE ANALYSIS; ODDS RATIO; PROSPECTIVE STUDIES; TREATMENT OUTCOME; VIRAL LOAD; WORLD HEALTH ORGANIZATION;

EID: 84860363350     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis005     Document Type: Review

References (28)

1. UNAIDS. Global report: UNAIDS report on the global AIDS epidemic 2010. Available at: http://www.unaids.org/globalreport/Global-report.htm. Accessed 7 March 2011.
2. National AIDS Control Organization, Department of AIDS Control, Ministry of Health and Family Welfare.Government of India. Annual report 2009-10. Available at: http://www.nacoonline.org. Accessed 28 October 2010.
3. World Health Organization, UNAIDS, UNICEF. Towards universal access, scaling up priority HIV/AIDS interventions in the health sector: progress report summary 2010. Available at: http://www.who.int/. Accessed 28 October 2010.
4. National AIDS Control Organization, Department of AIDS Control, Ministry of Health and Family Welfare.Government of India. List of ART centres as of January 2011. Available at: http://www.nacoonline.org. Accessed 7 June 2011.
5. Gilks CF, Crowley S, Ekpini R, et al. The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings. Lancet 2006; 368:505-10. (Pubitemid 44142772)
6. Deshpande A, Jauvin V, Magnin N, et al. Resistance mutations in subtype C HIV type 1 isolates from Indian patients of Mumbai receiving NRTIs plus NNRTIs and experiencing a treatment failure: resistance to AR. AIDS Res Hum Retroviruses 2007; 23:335-40. (Pubitemid 46418349)
7. Sen S, Tripathy SP, Patil AA, Chimanpure VM, Paranjape RS. High prevalence of human immunodeficiency virus type 1 drug resistance mutations in antiretroviral treatment-experienced patients from Pune, India. AIDS Res Hum Retroviruses 2007; 23:1303-8. (Pubitemid 350014773)
8. Sen S, Tripathy SP, Chimanpure VM, Patil AA, Bagul RD, Paranjape RS. Human immunodeficiency virus type 1 drug resistance mutations in peripheral blood mononuclear cell proviral DNA among antiretroviral treatment-naive and treatment-experienced patients from Pune, India. AIDS Res Hum Retroviruses 2007; 23:489-97. (Pubitemid 46700880)
9. Choudhury SD, Chaudhury AK, Kalra R, et al. Antiretroviral drug resistance mutations in the reverse transcriptase gene of HIV-1 isolates from northern Indian patients: a follow-up study. Arch Virol 2010; 155:563-9.
10. VidyaM, Saravanan S, Uma S, et al. Genotypic HIV type-1 drug resistance among patients with immunological failure to first-line antiretroviral therapy in south India. Antivir Ther 2009; 14:1005-9.
11. Gupta A, Saple DG, Nadkarni G, et al. One-, two-, and three-class resistance among HIV-infected patients on antiretroviral therapy in private care clinics:Mumbai, India. AIDS Res Hum Retroviruses 2010; 26:25-31.
12. Jordan MR, Bennett DE, Bertagnolio S, Gilks CF, Sutherland D. World Health Organization surveys to monitor HIV drug resistance prevention and associated factors in sentinel antiretroviral treatment sites. Antivir Ther 2008; 13:15-23. (Pubitemid 352019086)
13. National AIDS Control Organization, Department of AIDS Control, Ministry of Health and Family Welfare,Government of India. Antiretroviral therapy guidelines for HIV-infected adults and adolescents including post-exposure prophylaxis, 2007. Available at: http://www.nacoonline.org. Accessed 28 October 2010.
14. Liu TF, Shafer RW. Web resources for HIV type 1 genotypic-resistance test interpretation. Clin Infect Dis 2006; 42:1608-18. Epub 2006 Apr 28. Available at: http://hivdb. stanford. edu/. Accessed 21 and 28 November 2011.
15. Coetzee D, Hildebrand K, Boulle A, et al. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS 2004; 18:887-95. (Pubitemid 38553709)
16. Johannessen A, Naman E, Kivuyo SL, et al. Virological efficacy and emergence of drug resistance in adults on antiretroviral treatment in rural Tanzania. BMC Infect Dis 2009; 9:108.
17. Wester CW, Kim S, Bussmann H, et al. Initial response to highly active antiretroviral therapy in HIV-1C-infected adults in a public sector treatment program in Botswana. J Acquir Immune Defic Syndr 2005; 40:336-43. (Pubitemid 41533075)
18. Tam LW, Hogg RS, Yip B, Montaner JS, Harrigan PR, Brumme CJ. Performance of a World Health Organization first-line regimen (stavudine/lamivudine/ nevirapine) in antiretroviral-naive individuals in a Western setting. HIV Med 2007; 8:267-70. (Pubitemid 46901524)
19. Bussmann H, Wester CW, Thomas A, et al. Response to zidovudine/ didanosine-containing combination antiretroviral therapy among HIV-1 subtype C-infected adults in Botswana: two-year outcomes from a randomized clinical trial. J Acquir Immune Defic Syndr 2009; 51:37-46.
20. Garrido C, Zahonero N, Fernandes D, et al. Subtype variability, virological response and drug resistance assessed on dried blood spots collected from HIV patients on antiretroviral therapy in Angola. J Antimicrob Chemother 2008; 61:694-8. (Pubitemid 351321149)
21. Hanson DL, Adje-Touré C, Talla-Nzussouo N, et al. HIV type 1 drug resistance in adults receiving highly active antiretroviral therapy in Abidjan, Cote d'Ivoire. AIDS Res Hum Retroviruses 2009; 25:489-95.
22. Wang Xia, Yang Liting, Li Huiqin, et al. Factors associated with HIV virologic failure among patients on HAART for one year at three sentinel surveillance sites in China. Curr HIV Res 2011; 9:103-11.
23. Hosseinipoura MC, Oosterhoutc JJG, Weigel R, et al. The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS 2009; 23:1127-34.
24. Marconi VC, Sunpath H, Lu Z, et al. Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral regimen in KwaZulu Natal, South Africa. Clin Infect Dis 2008; 46:1589-97. (Pubitemid 351706742)
25. Ivers LC, Kendrick D, Doucette K, et al. Efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature. Clin Infect Dis 2005; 41:217-24. (Pubitemid 40962502)
26. Kantor R, Shafer RW, Follansbee S, et al. Evolution of resistance to drugs in HIV-1 infected patients failing antiretroviral therapy. AIDS 2004; 18:1503-11. (Pubitemid 39037474)
27. McMahon JH, Jordan MR, Kelley K, et al. Pharmacy adherence measures to assess adherence to antiretroviral therapy: review of the literature and implications for treatment monitoring. Clin Infect Dis 2011; 52:493-506.
28. Gupta RK, Hill A, Sawyer AW, et al. Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis. Lancet Infect Dis 2009; 9:409-17.